Pyroglutamate-modified amyloid beta peptides: Emerging targets for alzheimer's disease immunotherapy

Current Neuropharmacology

Volumn 11, Issue 5, 2013, Pages 491-498

  Perez Garmendia, Roxanna ^a   Gevorkian, Goar ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Alzheimer's disease; Amyloid beta; Glutaminyl cyclase; Immunotherapy; N terminal truncated amyloid beta; Pyroglutamate modified amyloid beta

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN N11; AMYLOID BETA PROTEIN N3; BAPINEUZUMAB; ENZYME INHIBITOR; GLUTAMINYL CYCLASE INHIBITOR; PRESENILIN 1; PYROGLUTAMIC ACID; SOLANEZUMAB; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; COGNITION; ENZYME INHIBITION; HUMAN; IMMUNOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC);

EID: 84884266807     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X11311050004     Document Type: Article

References (96)

1. Masters, C. L.; Simms, G.; Weinmann, N. A.; Multhaup, G.; McDonald, B. L.; Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A., 1985, 82(12), 4245-4249.
2. Walsh, D. M.; Selkoe, D. J. Deciphering the molecular basis of memory failure in Alzheimer's diseas. Neuron, 2004, 44(1), 181-193.
3. Haass, C; Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol., 2007, 8(2), 101-112.
4. LaFerla, F.; Green, K. N.; Oddo, S. Intracellular amyloid-p in Alzheimer's disease. Nat. Rev. Neurosci., 2007, 8, 499-509.
5. Gouras, G. K.; Tampellini, D.; Takahashi, R. H.; Capetillo-Zarate, E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol, 2010, 119(5), 523-541.
6. Ballard, C; Gauthier, S.; Corbett, A.; Brayne, C; Aarsland, D.; Jones, E. Alzheimer's disease. The Lancet, 2011, 377(9770), 1019-1031.
7. Ferreira, S. T.; Klein, W. L. The Ap oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol. Learn. Mem., 2011, 96(4), 529-543.
8. Vassar, R.; Bennet, B. D.; Babu-Khan, S.; Khan, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999, 286(5440), 735-741.
9. Selkoe, D. J. Alzheimer's disease: genes, proteins and therapy. Physiol. Rev., 2001, 81(2), 741-766.
10. Hook, V. Y.; Reisine, T. D. Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE1 in the constitutive secretory pathway. J. Neurosci. Res., 2003, 74(3), 393-405.
11. Mori, H.; Takio, K.; Ogawara, M.; Selkoe, D. J. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem., 1992, 267(24), 17082-17086.
12. Seubert, P.; Vigo-Pelfrey, C; Esch, F.; Lee, M.; Dovey, H.; Davis, D.; Sinha, S.; Schiossmacher, M.; Whaley, J.; Swindlehurst, C; McCormack, R.; Wolfert, R.; Selkoe, D.; Lieberburg, I.; Schenk, D. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature, 1992, 359, 325-327.
13. Miller, D. L.; Papayannopoulos, I. A.; Styles, J.; Bobin, S. A.; Lin, Y. Y.; Biemann, K.; Iqbal, K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys., 1993, 301(1), 41-52.
14. Saido, T. C; Iwatsubo, T.; Mann, D. M. A.; Shimada, H.; Ihara, Y.; Kawashima, S. Dominant and differential deposition of distinct pi-amyloid peptide species, ApN3(pE), in senile plaques. Neuron, 1995, 14, 457-466.
15. Saido, T. C; Yamao-Harigaya, W.; Iwatsubo, T.; Kawashima, S. Amino- and carboxyl-terminal heterogeneity of p-amyloid peptides deposited in human brain. Neurosci. Lett., 1996, 215, 173-176.
16. Naslund, J.; Karlstrom, A. R.; Tjernberg, L. O.; Schierhorn, A.; Terenius, L.; Nordstedt, C. High-resolution separation of amyloid beta-peptides: structural variants present in Alzheimer's disease amyloid. J. Neurochem., 1996, 67(1), 294-301.
17. Russo, C; Saido, T. C; DeBusk, L. M.; Tabaton, M.; Gambetti, P.; Teller, J. K. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Dowńs syndrome brains. FEBS Lett., 1997, 409(3), 411-416.
18. Tekirian, T. L.; Markesbery, W. R.; Russel, M. J.; Wekstein, D. R.; Patel, E.; Geddes, J. W. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J. Neuropathol. Exp. Neurol., 1998, 57(1), 76-94.
19. Larner, A. J. Hypothesis: amyloid p-peptides truncated at the N-terminus contribute to the pathogenesis of Alzheimer's disease. Neurobiol. Aging, 1999, 20, 65-69.
20. Kumar-Singh, S.; De Jonghe, C; Cruts, M.; Kleinert, R.; Wang, R.; Mercken, M.; De Strooper, B.; Vanderstichele, H.; Lofgren, A; Vanderhoevens, H.; Vanmechelen, E.; Kroisel, P. M.; Van Broeckhoven, C. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Hum. Mol. Genet, 2000, 9(18), 2589-2598.
21. Miravalle, L.; Calero, M.; Takao, M.; Roher, A. E.; Ghetti, B.; Vidal, R. Amino-terminally truncated Ap peptide species are the main component of cotton wool plaques. Biochemistry, 2005, 44, 10810-10821.
22. Vanderstichele, H.; De Meyer, G.; Andreasen, N.; Kostanjevecki, V.; Wallin, A.; Olsson, A.; Blennow, K.; Vanmechelen, E. Amino-truncated p-amyloid 42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin. Chem., 2005, 51(9), 1650-1660.
23. Huse, J. T.; Liu, K.; Pijak, D. S.; Carlin, D.; Lee, V. M. -Y.; Doms, R. W. p-Secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. J. Biol. Chem., 2002, 277(18), 16278-16284.
24. Lee, E. B.; Skovronsky, D. M.; Abtahian, F.; Doms, R. W.; Lee, V. M. Y. Secretion and intracellular generation of truncated Ap in p-site amyloid-p precursor protein-cleaving enzyme expressing human neurons. J. Biol. Chem., 2003, 278(7), 4458-4466.
25. Liu, K.; Solano, I.; Mann, D.; Lemere, C; Mercken, M.; Trojanowski, J. Q.; Lee, V. M. Y. Characterization of Ap11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Ap species in the pathogenesis of Alzheimer's disease. Acta Neuropathol., 2006, 112(2), 163-174.
26. Piccini, A.; Russo, C; Gliozzi, A.; Relini, A; Vitali, A.; Borghi, R.; Giliberto, L.; Armirotti, A.; D'Arrigo, C; Bachi, A.; Cattaneo, A.; Canale, C; Torrassa, S.; Saido, T. C; Markesbery, W.; Gambetti, P.; Tabaton, M. p-Amyloid Is Different in Normal Aging and in Alzheimer Disease. J. Biol. Chem., 2005, 280(40), 34186-34192.
27. Guntert, A.; Dobeli, H.; Bohrmann, B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience, 2006, 143, 461-475.
28. Hosoda, R.; Saido, T. C; Otvos, L. Jr.; Arai, T.; Mann, D. M.; Lee, V. M.; Trojanowski, J. Q.; Iwatsubo, T. Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J. Neuropathol. Exp. Neurol., 1998, 57(11), 1089-1095.
29. Gunn, A. P.; Masters, C. L.; Cherny, R. A. Pyroglutamate-Ap: role in the natural history of Alzheimer's disease. Int. J. Biochem. Cell Biol, 2010, 42(12), 1915-1918.
30. Jawhar, S.; Wirths, O.; Bayer, T. A. Pyroglutamate amyloid p (Ap): a hatchet man in Alzheimer Disease. J. Biol. Chem., 2011, 286(45), 38825-38832.
31. Sullivan, C. P.; Berg, E. A.; Elliot-Bryant, R.; Fishman, J. B.; McKee, A. C; Morin, P. J.; Shia, M. A.; Fine, R. E. Pyroglutamate-Ap 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Ap 11 forming central core. Neurosci. Lett., 2011, 505(2), 109-112.
32. Harigaya, Y.; Saido, T. C; Eckman, C. B.; Prada, C. M.; Shoji, M.; Younkin, S. G. Amyloid p protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimers disease brain. Biochem. Biophys. Res. Comm., 2000, 276(2), 422-427.
33. Portelius, E.; Bogdanovic, N.; Gustavsson, M. K.; Volkmann, I.; Brinkmalm, G.; Zetterberg, H.; Winblad, B.; Blennow, K. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol, 2010, 120(2), 185-193.
34. Wirths, O.; Bethge, T.; Marcello, A.; Harmeier, A.; Jawhar, S.; Lucassen, P. J.; Milthaup, G. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J. Neural. Transm., 2010, 117(1), 85-96.
35. Wirths, O.; Erck, C; Martens, H.; Harmeier, A.; Geumann, C; Jawhar, S.; Kumar, S.; Multhaup, G.; Walter, J.; Ingelsson, M.; Degerman-Gunnarsson, M.; Kalimo, H.; Huitinga, I.; Lannfelt, L.; Bayer, T. A. Identification of low molecular weight pyroglutamate Ap oligomers in Alzheimer Disiease. A novel tool for therapy and diagnosis. J. Biol. Chem., 2010, 285(53), 41517-41524.
36. Sergeant, N.; Bombois, S.; Ghestem, A.; Drobecq, H.; Kostanjevecki, V.; Missiaen, C; Wattez, A.; David, J. P.; Vanmechelen, E.; Sergheraert, C; Delacourte, A. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem., 2003, 85, 1581-1591.
37. Pike, C. J.; Overman, M. J.; Cotman, C. W. Amino-terminal Deletions Enhance Aggregation of beta-Amyloid Peptides in vitro. J. Biol. Chem., 1995, 270(41), 23895-23898.
38. He, W.; Barrow, C. J. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry, 1999, 38, 10871-10877.
39. Russo, C; Violani, E., Salis, S.; Venezia, V.; Dolcini, V.; Damonte, G.; Benatti, U.; D'Ariigo, C; Patrone, E.; Carlo, P.; Schettini, G. Pyrglutamate-modified amyloid p-peptides -ApN3(pE) - strongly affect cultured neuron and astrocyte survival. J. Neurochem., 2002, 82, 1480-1489.
40. Schilling, S.; Lauber, T.; Schaupp, M.; Manhart, S.; Scheel, E.; Bohm, G.; Demuth, H. U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry, 2006, 45(41), 12393-12399.
41. Youssef, I.; Florent-Bechard, S.; Malaplate-Armand, C; Koziel, V.; Bihain, B.; Olivier, J. L.; Leininger-Muller, B.; Kriem, B.; Oster, T.; Pillot, T. N-truncated amyloid-p oligomers induce learning impairment and neuronal apoptosis. Neurobiol. Aging, 2007, 29, 1319-1333.
42. D'Arrigo, C; Tabaton, M.; Perico, A. N-terminal truncated pyroglutamyl p amyloid peptide Appy3-42 shows a faster aggregation kinetics than the full-length Ap1-42. Biopolymers, 2009, 91(10), 861-873.
43. Nussbaum, J. M.; Schilling, S.; Cynis, H.; Silva, A.; Swanson, E.; Wangsanut, T.; Tayler, K.; Wiltgen, B.; Hatami, A.; Ronicke, R.; Reymann, K.; Hutter-Paier, B.; Alexandru, A.; Jagla, W.; Graubner, S.; Glabe, C. G.; Demuth, H. U.; Bloom, G. S. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-p. Nature, 2012, 485, 651-655.
44. Sun, N.; Hartmann, R.; Lecher, J.; Stoldt, M.; Funke, S. A.; Gremer, L.; Ludwig, H. H.; Demuth, H. U.; Kleinschmidt, M.; Willbold, D. Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-p using NMR stectroscopy. J. Pept. Sci., 2012, 18, 691-695.
45. Selkoe, D. J.; Abraham, C. R.; Podlisny, M. B.; Duffy, L. K. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J. Neurochem., 1986, 46(6), 1820-1834.
46. Miller, D. L.; Currie, J. R.; Iqbal, K.; Potempska, A.; Styles, J. Relationships among the cerebral amyloid peptides and their precursors. Ann. Med., 1989, 21(2), 83-87.
47. Naslund, J.; Schierhorn, A.; Hellman, U.; Lannfelt, L.; Roses, A. D.; Tjernberg, L. O.; Silberring, J.; Gandy, S. E.; Winblad, B.; Greengard, P.; Nordstedt, C; Terenius, L. Relative abundance of Alzheimer Ap amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. USA, 1994, 91, 8378-8382.
48. Hartig, W.; Goldhammer, S.; Bauer, U.; Wegner, F.; Wirths, O.; Bayer, T. A.; Grosche, J. Concomitant detection of p-amyloid peptides with N-terminal truncation and diffeent C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. J. Chem. Neuroanatomy, 2010, 40, 82-92.
49. Iwatsubo, T.; Saido, T. C; Mann, D. M.; Lee, V. M.; Trojanowski, J. Q. Full-length amyloid beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am. J. Pathol, 1996, 149(6), 1823-1830.
50. Kuo, Y. M.; Emmerling, M. R.; Woods, A. S.; Cotter, R. J.; Roher, A. E. Isolation, Chemicalm characterization and quantitation of Ap 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem. Biophys. Res. Commun., 1997, 237, 188-191.
51. Mandler, M.; Rockenstein, E.; Ubhi, K.; Hansen, L.; Adame, A.; Michael, S.; Galasko, D.; Santic, R.; Mattner, F.; Masliah, E. Detection of peri-synaptic amyloid-b pyroglutamate aggregates in early stages of Alzheimer's disease and in AbPP transgenic mice using a novel monoclonal antibody. J. Alzheimers Dis., 2012, 28(4), 783-794.
52. Bayer, T. A.; Wirths, O. Intraneuronal Ap is a trigger for neuronal loss: can this be translated into human pathology? Biochem. Soc. Trans., 2011, 39(4), 857-861.
53. De Kimpe, L.; van Haastert, E. S.; Kaminari, A.; Zwart, R.; Rutjes, H.; Hoozemans, J. J. M.; Scheper, W. Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Ap pathology at the lysosome. AGE 2012, DOI 10.1007/s11357-012-9403-0.
54. Schlenzig, D.; Ronicke, R.; Cynis, H.; Ludwig, H. H.; Scheel, E.; Reymann, K.; Saido, T.; Hause, G.; Schilling, S.; Demuth, H. U. N-terminal pyroglutamate formation of Ap38 and Ap40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. J. Neurochem., 2012, 121(5), 774-784.
55. Kayed, R.; Head, E.; Thompson, J. L.; McIntire, T. M.; Milton, S. C; Cotman, C. W.; Glabe, C. G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300(5618), 486-489.
56. Acero, G.; Manoutcharian, K.; Vasilevko, V.; Munguia, M. E.; Govezensky, T.; Coronas, G.; Luz-Madrigal, A.; Cribas, D. H.; Gevorkian, G. Immunodominant epitope and properties of pyroglutamate-modified Ap-specific antibodies produced in rabbits. J. Neuroimmunol, 2009, 213, 39-46.
57. Kawarabashi, T.; Younkin, L. H.; Saido, T. C; Shoji, M.; Ashe, K. H.; Younkin, S. G. Age-dependent changes in brain, CSF, and plasma amyloid(beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci., 2001, 21(2), 372-381.
58. Kalback, W.; Watson, M. D.; Kokjohn, T. A.; Kuo, Y. M.; Weiss, N.; Luehrs, D. C; Lopez, J.; Brune, D.; Sisodia, S. S.; Staufenbiel, M.; Emmerling, M.; Roher, A. E. APP transgenic mice Tg2576 accumulate Ap peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry, 2002, 41, 922-928.
59. Schilling, S.; Zeitschel, U.; Hoffmann, T.; Heiser, U.; Francke, M.; Kehlen, A.; Holzer, M.; Hutter-Paier, B.; Prokesch, M.; Windisch, M.; Jagla, W.; Schlenzig, D.; Lindler, C; Rudolph, T.; Reuter, G.; Cynis, H.; Montag, D.; Demuth, H. U.; Rossner, S. Glutaminyl cyclase inhibition attenuates pyroglutamate Ap and Alzheimer's disease-like pathology. Nat. Med., 2008, 14(10), 1106-1111.
60. Casas, C; Sergeant, N.; Itier, J. M.; Blanchard, V.; Wirths, O.; van der Kolk, N.; Vingtdeux, V.; van de Steeg, E.; Ret, G.; Canton, T.; Drobecq, H.; Clark, A.; Bonici, B.; Delacourte, A.; Benavides, J.; Schmitz, C; Tremp, G.; Bayer, T. A.; Benoit, P.; Pradier, L. Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated Ap42 Accumulation in a Novel Alzheimer Transgenic Model. Am. J. Pathol., 2004, 165(4), 1289-1300.
61. Bayer, T. A.; Breyhan, H.; Duan, K.; Rettig, J.; Wirths, O. Intraneuronal p-amyloid is a major risk factor - novel evidence from the APP/PS1KI mouse model. Neurodegener. Dis., 2008, 5(3-4), 140-142.
62. Breyhan, H.; Wirths, O.; Duan, K.; Marcello, A.; Rettig, J.; Bayer, T. A. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol., 2009, 117(6), 677-685.
63. Wirths, O.; Weis, J.; Kayed, R.; Saido, T. C; Bayer, T. A. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol. Aging, 2007, 28, 1689-1699.
64. Wirths, O.; Breyhan, H.; Cynis, H.; Schilling, S.; Demuth, H. U.; Bayer, T. A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol., 2009, 118(4), 487-496.
65. Alexandru, A.; Jagla, W.; Graubner, S.; Becker, A.; Bauscher, C; Kohlmann, S.; Sedlmeier, R.; Raber, K. A.; Cynis, H.; Ronicke, R.; Reymann, K. G.; Petrasch-Parwez, E.; Hartlage-Rubsamen, M.; Waniek, A.; Rossner, S.; Schilling, S.; Osmand, A. P.; Demuth, H. U.; von Horsten, S. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Ab is induced by pyroglutamate-Ap formation. J. Neurosci., 2011, 31(36), 12780-12801.
66. Jawhar, S.; Wirths, O.; Schilling, S.; Graubner, S.; Demuth, H. U.; Bayer, T. A. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Ab formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J. Biol. Chem., 2011, 286(6), 4454-4460.
67. Wittnam, J. L.; Portelius, E.; Zetterberg, H.; Gustavsson, M. K.; Schilling, S.; Koch, B.; Demuth, H. U.; Blennow, K.; Wirths, O.; Bayer, T. A. Pyroglutamate amyloid p (Ap) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer's disease. J. Biol. Chem., 2012, 287(11), 8154-8162.
68. Schilling, S.; Hoffmann, T.; Manhart, S.; Hoffmann, M.; Demuth, H. U. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett, 2004, 563, 191-196.
69. Fischer, W. H.; Spiess, J. Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides. Proc. Natl. Acad. Sci. USA, 1987, 84(11), 3628-3632.
70. Cynis, H.; Scheel, E.; Saido, T. C; Schilling, S.; Demuth, H. U. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-p. Biochemistry, 2008, 47, 7405-7413.
71. Schilling, S.; Appl, T.; Hoffmann, T.; Cynis, H.; Schulz, K.; Jagla, W.; Friedrich, D.; Wermann, M.; Buchholz, M.; Heiser, U.; von Horsten, S.; Demuth, H. U. Inhibition of glutaminyl cyclase prevents prevents pGlu-Ap formation after intracortical/hippocampal microinjection in vivo/insitu. J. Neurochem., 2008, 106(3), 1225-1236.
72. De Kimpe, L.; Bennis, A.; Zwart, R.; van Haastert, E. S.; Hoozemans, J. J. Disturbed Ca2+ homeostasis increases glutaminyl cyclase expression; connecting two early pathogenic events in Alzheimer's disease in vitro. PLoS ONE 2012, 7(9), e44674.
73. Valenti, M. T.; Bolognin, S.; Zanatta, C; Donatelli, L.; Innamorati, G.; Pampanin, M.; Zanusso, G.; Zatta, P.; Carbonare, L. D. Increased glutaminyl cyclase expression in peripheral blood of Alzheimer's disease patients. J. Alzheimers Dis., 2013, DOI: 10.3233/JAD-120517.
74. Hartlage-Rubsamen, M.; Morawski, M.; Waniek, A.; Jager, C; Zeitschel, U.; Koch, B.; Cynis, H.; Schilling, S.; Schliebs, R.; Demuth, H. U.; Rossner, S. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Ap deposits in hippocampus via distinct cellular mechanisms. Acta neuropathol, 2011, 121(6), 705-719.
75. Cynis, H.; Schilling, S.; Bodnar, M.; Hoffmann, T.; Heiser, U.; Saido, T. C; Demuth, H. U. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim. Biophys. Acta, 2006, 1764, 1618-1625.
76. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Liao, Z.; Lieberburg, I.; Motter, R.; Mutter, L.; Soriano, F.; Shopp, G.; Vasquez, N.; Vandevert, C; Walker, S.; Wogulis, M.; Yednock, T.; Games, D.; Seubert, P. Immunization with amyloid-p attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999, 400(6740), 173-177.
77. Bard, F.; Cannon, C; Barbour, R.; Burke, R. L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F., Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid-p peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat. Med., 2000, 6(8), 916-919.
78. Lemere, C.A.; Beierschmitt, A.; Iglesias, M.; Spooner, E.T.; Bloom, J.K.; Leverone, J.F.; Zheng, J.B.; Seabrook, T.J.; Louard, D.; Li, D.; Selkoe, D.J.; Palmour, R.M.; Ervin, F.R. Alzheimer's disease Ap vaccine reduces central nervous system Ap levels in a non-human primate, the Caribbean vervet. Am. J. Pathol, 2004, 165(1), 283-297.
79. Wilcock, D. M.; Rojiani, A.; Rosenthal, A.; Levkowitz, G.; Subbarao, S.; Alamed, J.; Wilson, D.; Wilson, N.; Freeman, M. J.; Gordon, M. N.; Morgan, D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci., 2004, 24(27), 6144-6151.
80. Brody, D. L.; Holtzman, D. M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci., 2008, 31, 175-193.
81. Head, E.; Pop, V.; Vasilevko, V.; Hill, M.; Saing, T.; Sarsoza, F.; Nistor, M.; Christie, L. A.; Milton, S.; Glabe, C; Barrett, E.; Cribbs, D. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J. Neurosci., 2008, 28(14), 3555-3566.
82. Biscaro, B.; Lindvall, O.; Hock, C; Ekdahl, C. T.; Nitsch, R. M. Ap immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. J. Neurosci., 2009, 29(45), 14108-14119.
83. Morgan, D. Immunotherapy for Alzheimer's disease. J. Intern. Med., 2011, 269(1), 54-63.
84. Lemere, C. A.; Masliah, E. Can Alzheimer disease be prevented by amyloid-p immunotherapy? Nat. Rev. Neurol, 2010, 6(2), 108-119.
85. Roher, A. E.; Maarouf, C. L.; Daugs, I. D.; Kokjohn, T. A.; Hunter, J. M.; Sabbagh, M. N.; Beach, T. G. Neuropathology and amyloid-b spectrum in a bapineuzumab immunotherapy recipient. J. Alzheimers Dis., 2011, 24, 315-325.
86. Bacskai, B. J.; Kajdasz, S. T.; McLellan, M. E.; Games, D.; Seubert, P.; Schenk, D.; Hyman, B. T. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J. Neurosci., 2002, 22, 7873-7878.
87. Zago, W.; Buttini, M.; Comery, T. A.; Nishioka, C; Gardai, S. J.; Seubert, P.; Games, D.; Bard, F.; Schenk, D.; Kinney, G. G. Neutralization of soluble, synaptotoxic amyloid p species by antibodies is epitope speicifc. J. Neurosci., 2012, 32, 2696-2702.
88. Perez-Garmendia, R.; Ibarra-Bracamontes, V.; Vasilevko, V.; Luna-Munoz, J.; Mena, R.; Govezensky, T.; Acero, G.; Manoutcharian, K.; Cribs, D. H.; Gevorkian, G. Anti-11 [E]-pyroglutamate-modified amyloid p antibodies cross-react with other pathological Ap species: relevante for immunotherapy. J. Neuroimmunol, 2010, 229, 248-255.
89. Venkataramani, V.; Wirths, O.; Budka, H.; Hartig, W.; Kovacs, G. G.; Bayer, T. A. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-b in a fraction of amyloid-b deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. J. Alzheimers Dis., 2012, 29(2), 361-371.
90. Frost, J. L.; Liu, B.; Kleinschmidt, M.; Schilling, S.; Demuth, H. U.; Lemere, C. A. Passive immunization against pyroglutamate-3 amyloid-b reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegenerative Dis., 2012, 10, 265-270.
91. DeMattos, R.; Lu, J.; Tang, Y.; Racke, M. M.; DeLong, C. A; Tzaferis, J. A.; Hole, J. T.; Forster, B. M.; McDonnell, P. C; Liu, F.; Kinley, R. D.; Jordan, W. H.; Hutton, M. L. A plaque-specific antibody clears existing p-amyloid plaques in Alzheimer's disease mice. Neuron, 2012, 76, 908-920.
92. Tomljenovic, L.; Shaw, C. A. Aluminum vaccine adjuvants: are they safe? Curr. Med. Chem., 2011, 18, 2630-2637.
93. Siemers, E. R.; Friedrich, S.; Dean, R A.; Gonzalez, C. R.; Farlow, M. R.; Paul, S. M.; DeMattos, R. B. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin. Neuropharmacol, 2010, 33(2), 67-73.
94. Samadi, H.; Sultzer, D. Solanezumab for Alzheimer's disease. Expert Opin. Biol. Ther., 2011, 11(6), 787-798.
95. Farlow, M.; Arnold, S. E.; van Dyck, C. H.; Aisen, P. S.; Snider, B. J.; Porsteinsson, A. P.; Friedrich, S.; Dean, R. A; Gonzalez, C; Sethuraman, G.; DeMattos, R. B.; Mohs, R.; Paul, S. M.; Siemers, E. R. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement., 2012, 8, 261-271.
96. Imbimbo, B. P.; Ottonello, S.; Frisardi, V.; Solfrizzi, V.; Greco, A.; Seripa, D.; Pilotto, A; Panza, F. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev. Clin. Immunol, 2012, 8(2), 135-149.